Physician profile
Nancy Enger
NPI 1306107875
$2,361.46
in general payments reported to CMS, 2019-2025
26 companies · $904 in 2025
The $904 reported for 2025 was more than what 83% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $148 · 2023: $642 · 2024: $667 · 2025: $904.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,213.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $304.97 | 2023-2025 | |
| Abbott Laboratories | $265.83 | 2023-2025 | Mitraclip, Freestyle Libre 3, Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals LP | $244.99 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $220.88 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Boston Scientific Corporation | $164.01 | 2025 | Watchman Flx |
| Glaxosmithkline, LLC. | $163.70 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $133.62 | 2023-2025 | |
| Amgen INC. | $103.74 | 2023-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $96.41 | 2022-2025 | Wegovy |
| Pfizer INC. | $74.13 | 2023-2025 | |
| Aimmune Therapeutics, INC. | $70.78 | 2024-2025 | Zenpep, Vowst |
| Exact Sciences Corporation | $59.51 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $55.94 | 2022-2024 | |
| Sumitomo Pharma America, INC. | $54.54 | 2024-2025 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $54.13 | 2024-2025 | Trintellix |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $45.34 | 2022-2023 | Myrbetriq |
| Merck Sharp & Dohme LLC | $41.03 | 2023 | Belsomra, Steglatro |
| Nestle Healthcare Nutrition INC. | $34.12 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $32.96 | 2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $26.16 | 2022-2023 | Quviviq |
| Verona Pharma, INC. | $25.02 | 2025 | Ohtuvayre |
| Optinose US, INC. | $21.65 | 2025 | |
| Dexcom, INC. | $20.42 | 2024 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $17.13 | 2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $15.42 | 2022 | |
| Ironwood Pharmaceuticals, INC | $15.03 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Enger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.